AsiaNet-Pakistan Premier Editorial Content and Press Release Distribution Service
Karachi, Haleon Pakistan Limited informed Pakistan Stock Exchange about the recommendations made by the board of directors in the meeting held at Karachi on March 14, 2023.
The agenda of the meeting was discussion of profit and loss account for Year ended December 31, 2022 which portrayed a profit of Rs. 326,783,000 with earnings per share 2.78 basic and diluted respectively.
Further, nil payment of cash dividend, bonus shares and right shares was agreed.
Furthermore, the share transfer books of the company will remain closed from April 20, 2023 to April 27, 2023 (both days inclusive).
The announcement is available at:
https://dps.psx.com.pk/download/document/204226.pdf
Haleon Pakistan Limited formerly known as “GlaxoSmithKline Pakistan Limited” was created January 1st, 2001 through the merger of SmithKline and French of Pakistan Limited, Beecham Pakistan (Private) Limited and Glaxo Welcome (Pakistan) Limited and stands today as a pharmaceutical company in Pakistan.
GlaxoSmithKline Pakistan Limited is incorporated in Pakistan as a limited liability company and. It is engaged in manufacturing and marketing of research based ethical specialties and pharmaceutical products. The Company is a subsidiary of S.R. One International B.V., incorporated in Netherlands, whereas its ultimate parent company is GlaxoSmithKline Plc, UK (GSK Plc). GSK Pakistan operates mainly in two industry segments: Pharmaceuticals and consumer healthcare.
The share of the Company are 318,467,278. The Earnings per shares of the company is 10.60 in 2020 which was 9.55 in 2019. The profit after taxation is Rs. 3,375,240,000 in 2020 which was 3,041,123,000 in 2019.